Showing results (81-90 of 111) with videos related to
Sort By:
Pageof 12
Blood Advances|June 20, 2020
American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic painAmanda M Brandow, C Patrick Carroll, Susan Creary, et al.Blood|May 31, 2013
Gene-centric association study of acute chest syndrome and painful crisis in sickle cell disease patientsGeneviève Galarneau, Sean Coady, Melanie E Garrett, et al.British Journal of Haematology|February 8, 2020
Regulation of iron homeostasis through the erythroferrone-hepcidin axis in sickle cell diseaseAbhishek A Mangaonkar, Fahim Thawer, James Son, et al.Human Molecular Genetics|January 31, 2025
A replication study of novel fetal hemoglobin-associated genetic variants in sickle cell disease-only cohortsYann Ilboudo, Nicolas Brosseau, Ken Sin Lo, et al.Transfusion|June 3, 2008
Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusionsEllen B Fung, Paul R Harmatz, Meredith Milet, et al.American Journal of Hematology|March 7, 2024
Mortality in adults with sickle cell disease: Results from the sickle cell disease implementation consortium (SCDIC) registryFranklin Njoku, Norma Pugh, Donald Brambilla, et al.Journal of Medicinal Chemistry|July 20, 2011
Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptomsJean Leandro dos Santos, Carolina Lanaro, Lídia Moreira Lima, et al.Experimental Hematology|November 8, 2017
A thalidomide-hydroxyurea hybrid increases HbF production in sickle cell mice and reduces the release of proinflammatory cytokines in cultured monocytesCarolina Lanaro, Carla F Franco-Penteado, Fabio H Silva, et al.British Journal of Haematology|May 20, 2011
Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell diseaseElliott Vichinsky, Françoise Bernaudin, Gian Luca Forni, et al.Clinical Science (London, England : 1979)|November 11, 2024
Enhanced vasoconstriction in sickle cell disease is dependent on ETA receptor activationJohn Miller Allan, Brandon M Fox, Malgorzata Kasztan, et al.Pageof 12